ACTIVE HALF-LIFE: 1 DAY
CLASSIFICATION: THYROID HORMONE
DOSAGE: 25-75 MCG/DAY
ACNE: NO
WATER RETENTION: NO
HBR: YES
HEPATOXITY: NO
AROMATIZATION: NO
ACTIVE SUBSTANCE: LIOTHYRONINE SODIUM
FORM: 50 PILLS X 25 MCG
MANUFACTURER: EMINENCE LABS
CHARACTERISTICS
ACTIVE HALF-LIFE 1 DAY
CLASSIFICATION THYROID HORMONE
DOSAGE 25-75 MCG/DAY
ACNE NO
WATER RETENTION NO
HBR YES
HEPATOTOXICITY NO
AROMATIZATION NO
ACTIVE SUBSTANCE LIOTHYRONINE SODIUM
FORM 50 PILLS X 25 MCG
MANUFACTURER HILMA BIOCARE
DISEASE INDICATIONS:
Alagille syndrome
MANUFACTURER:
Mirum Pharmaceuticals
USAGE:
Oral
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Livmarli (maralixibat) is a prescription medication that belongs to the drug class of bile acid transporter inhibitors. It is used to treat cholestatic pruritus (itch) in patients with Alagille syndrome who are at least 1 year old.
CHARACTERISTICS
ACTIVE HALF-LIFE 4-5 HOURS
CLASSIFICATION PDE5 INHIBITOR
DOSAGE WOMEN 100 MG/DAY
ACNE NO
WATER RETENTION NO
HBR POSSIBLE
HEPATOTOXICITY NO
AROMATIZATION NO
ACTIVE SUBSTANCE SILDENAFIL
FORM 4 PILLS X 100 MG
MANUFACTURER AJANTA PHARMA
DISEASE INDICATIONS: Cystic Fibrosis
MANUFACTURER: Gador SA
USAGE: Oral
MEDICINE APPROVED BY:
ANMAT (ARG)
Lucaftor is not a standalone medication but a combination therapy that consists of two active ingredients: lumacaftor and ivacaftor. This combination medication is used for the treatment of a specific genetic disorder known as cystic fibrosis (CF). It is designed to address the underlying cause of CF in individuals who have a specific mutation in the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) gene.
Lupkynis, known by its generic name Voclosporin, is a prescription medication used in the treatment of certain autoimmune diseases, primarily lupus nephritis.
DISEASE INDICATIONS: Breast Cancer, Gynaecological Cancer
MANUFACTURER: AstraZeneca AB
USAGE: Oral
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Health Canada
Therapeutic Goods Administration (TGA)
Medsafe (NZ)
Lynparza, also known by its generic name Olaparib, represents a pivotal breakthrough in the field of oncology, specifically in the treatment of certain types of cancer, by harnessing the power of targeted therapy.